Unlock instant, AI-driven research and patent intelligence for your innovation.

Laser-based vaccine adjuvants

a vaccine and laser technology, applied in the field of laser-based vaccine adjuvants, can solve the problems of few chemical or biological adjuvants approved for human use in the west, difficult to develop adjuvants with sufficient efficacy and safety, and aluminum salts

Inactive Publication Date: 2011-03-10
OOO NPT MBP GORMEZIS
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0009]The invention further provides methods to increase HSP 70 concentration and/or Langerhans cell concentration at or near the site of laser exposure as compared to a sit

Problems solved by technology

Although the new generations of vaccines are more targeted by design, they are also far less immunogenic and typically require powerful adjuvants to induce sufficient immune responses in the human body.
It has also been challenging to develop adjuvants with sufficient efficacy and safety to satisfy the stringent requirements of Western regulatory agencies.
Currently, very few chemical or biological adjuvants are approved for human use in the West.
Aluminum salts also cause side effects in a certain percentage of the population that receives such vaccinations.
However, most of these also have a high potential for side effects and have therefore not been approved for human use.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Laser-based vaccine adjuvants
  • Laser-based vaccine adjuvants
  • Laser-based vaccine adjuvants

Examples

Experimental program
Comparison scheme
Effect test

example 1

Secretion of Hsp70 in Response to the Cu Laser Treatment In Vitro

[0139]Fibroblasts cells derived from mouse embryo were cultured in the Petri dish using the Eagle or No. 199 medium for 24 h. Cell culture was exposed to the light beam of the Cu laser. The levels of HSP70 have been determined before and after irradiation using antibodies to Hsp70 (Russian Patent No. 2242764 7, Aug. 2003. After a 1 minute exposure, the separated supernatant solution displayed 350% increase of the extracellular HSP70, from 3.2 to 11.2 ng / L. The culture cells remained viable after laser irradiation as established by staining with the toluidine blue 0.2%

example 2

Effects of the Cu Laser Irradiation on the Skin In Vivo

[0140]Healthy white mice (CBA, Rappolovo, 50 animals) were treated using Cu laser by exposing a section of an ear to the laser light with a diameter of 5 mm over a period of 1-3 min. After the experiments, the animals were sacrificed at different time points. Immunohistochemical staining using antibodies to HSP70 (Russian Patent No. 2242764, 7, Aug. 2003) of the ventricular epidermal sheets of the ear (FIG. 6) provided a qualitative estimate of the increased levels of the secreted HSP70 as compared to the tissue from untreated ear from the same animal. These data were supported by the results of immunoblotting analysis of the processed ventricular epidermal sheets tissues though these results did not differentiate between secreted and intracellular HSP70. Immunoblotting for HSP70 showed that the combination of the two different wavelengths of light increased the quantity and duration of HSP70 secretion over single wavelengths, a...

example 3

Enhanced Antibody Production in Response to Vaccine Administered with Cu Laser

[0141]In a group of 125 healthy white mice (CBA, Rappolovo), 50 animals received 50 μL of a commercial H3N2 influenza vaccine (VAXIGRIP®, Aventis Pasteur) by subcutaneous injection to the left ear and served as a control group. In an experimental group, 50 mice were administered the same vaccine together with laser treatment (Cu laser at 578 / 511 nm, 1-3 ns pulses at 10 MHz) of the left ear. Of the 50 animals treated with laser, a subgroup of 25 animals was a subject of a one minute exposure whereas another subgroup of 25 mice was a subject of a two-minute exposure. An additional experimental set of 25 mice received the vaccine and exogenous bovine HSP70 (10 μg per injection, dissolved in 50 μL saline solution). The animals were sacrificed and antibody titers were measured 28 days after vaccination following a standard literature protocol [“The immune drugs for grippe prophylactic and diagnostic effectivene...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Timeaaaaaaaaaa
Poweraaaaaaaaaa
Frequencyaaaaaaaaaa
Login to View More

Abstract

The invention is directed to a vaccine for generating an enhanced immune response in a subject previously exposed to non-destructive laser radiation, as compared to an immune response in a subject previously non-exposed to non-destructive laser radiation. The invention is also directed to use of a composition comprising a vaccine for use in combination with non-destructive laser radiation for generating an enhanced immune response from a subject, as compared to an immune response without the use of laser radiation. The laser exposure acts as an adjuvant for the vaccine, increasing the efficacy and / or potency of the vaccine.

Description

RELATED APPLICATIONS[0001]This application is a Continuation of International Application No. PCT / IB2008 / 002637 filed on Oct. 6, 2008, which claims priority to Russian Patent Application Nos. RU 2007113393, filed 4 Oct. 2007, and RU 2008121934, filed 27 May 2008, both of which are incorporated herein by reference in their entirety.BACKGROUND OF THE INVENTION[0002]As the use of killed whole or attenuated live vaccines of the previous century gives way to the use of more sophisticated subunit protein and DNA vaccines that will characterize vaccines in next several decades, finding safe and effective vaccine adjuvants is becoming increasingly important. Although the new generations of vaccines are more targeted by design, they are also far less immunogenic and typically require powerful adjuvants to induce sufficient immune responses in the human body. It has also been challenging to develop adjuvants with sufficient efficacy and safety to satisfy the stringent requirements of Western ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/00A61P31/00
CPCA61K39/095C12N2760/16034A61K39/292A61K39/39A61K2039/53A61K2039/545A61K2039/55516C12N2730/10134C12N2760/16134A61N2005/0662A61N5/0613A61N2005/0659A61N2005/067A61K39/29C12N7/00C12N2750/00034A61K39/145A61K39/12A61P31/00A61N5/067
Inventor ONIKIENKO, SERGEY B.ZEMLYANOI, ALEXANDER V.MARGULIS, BORIS A.GUZHOVA, IRINA V.PIMENOVA, ANNA A.
Owner OOO NPT MBP GORMEZIS